Working… Menu

CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03086200
Recruitment Status : Recruiting
First Posted : March 22, 2017
Last Update Posted : January 15, 2019
University of Southern California
LA Biomed at Harbor-UCLA
The Los Angeles Lesbian, Gay, Bisexual, and Transgender Center
The Family Health Centers of San Diego
Information provided by (Responsible Party):
California Collaborative Treatment Group

Brief Summary:
CCTG 603 is an open-label, two-arm, randomized (1:1) clinical demonstration project to determine if brief Motivational Interviewing (MI-B) added to a text-message based adherence intervention (iTAB) improves adherence to PrEP among transgender persons.

Condition or disease Intervention/treatment Phase
Patient Adherence HIV Seronegativity Behavioral: brief Motivational Interviewing Not Applicable

Detailed Description:

A total of 300 HIV-uninfected transgender or gender non-conforming individuals, defined as currently identifying as a gender different from sex assigned at birth, with high-risk transmission behavior will be enrolled into this study. Each participant will be followed for a maximum of 48 weeks after enrollment. The primary endpoint will be measured at 48 weeks, or the last week on study if the participant is discontinued early.

All participants will start PrEP with TDF / FTC fixed dose combination taken once daily. Subjects will be randomized (1:1) to the iTAB text messaging adherence reminder intervention either with or without brief motivational interviewing (MI-b) for suboptimal adherence. All participants will receive the iTAB system to provide personalized, automated text messages to support and monitor adherence. In the MI-b arm, poor adheres by iTAB reporting will receive targeted MI-b via telephone.

Both groups will receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)
Actual Study Start Date : June 23, 2017
Estimated Primary Completion Date : April 6, 2020
Estimated Study Completion Date : April 6, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: iTAB + SOC Control Arm
Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
Experimental: iTAB + MI-b Intervention Arm
Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
Behavioral: brief Motivational Interviewing

All study participants will receive daily dosing text message reminders.

Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule.

Primary Outcome Measures :
  1. PrEP Adherence [ Time Frame: Baseline up to Week 48 ]
    To compare adherence to fixed dose TDF/FTC, as measured by intracellular levels of TFV-DP > 1246 fmol/punch, between subjects randomized to receive iTAB with versus without brief Motivational Interviewing, when used for adherence support to pre-exposure prophylaxis among transgender individuals at elevated risk for HIV acquisition.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Transgender or Gender Non-conforming, defined as identifying with a gender different from sex assigned at birth.
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Transgender identity, defined as identifying differently from sex assigned at birth
  • Age 18 years or older
  • Risk of acquisition of HIV as evident by one or more of the following:

Has at least one HIV infected sexual partner for ≥4 weeks


Anticipated or concern of unprotected anal or vaginal sex with a partner in the next 3 months


Any partner in the past 12 months AND at least one of the following:

  1. any condomless anal or vaginal sex in the past 12 months
  2. any STI diagnosed or reported in the past 12 months
  3. exchange of money, gifts, shelter, or drugs for sex


PEP-use in the past 12 months

  • Negative for HIV infection by nucleic acid test (NAT) or other sensitive method such as 4th generation antigen/antibody test
  • Acceptable renal function as measured by calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault formula (eCcr (male) in mL/min = [(140 - age in years) x (lean body weight in kg)] / (72 x serum creatinine in mg/dL) in the past 30 days

Exclusion Criteria:

  • Unable to give informed consent
  • Active hepatitis B defined by a positive hepatitis B surface antigen (HBsAg)
  • Substantial medical condition that, in the opinion of the investigator, would preclude participation, as defined by

    • gastrointestinal condition that would impair absorption of study drugs
    • known condition of reduce bone density (e.g. osteoporosis or osteogenesis imperfect) that significantly elevate the risk of bone fracture
    • neurological or severe psychiatric condition that would significantly impair the ability to adhere to PrEP
    • tubular or glomerular kidney disease that could be exacerbated by tenofovir
    • other medical condition that would unacceptably increase the risk of harm from study drug or significantly impair the ability to adhere to PrEP
  • Suspected sensitivity or allergy to the study drug or any of its components
  • Currently using an essential product or medication that interacts with the study drug such as the following:

    • other antiretroviral agent (including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors or investigational antiretroviral agents) - if currently on TDF/FTC for PEP or PrEP they can switch to study provided drug but can not continue any other antiretroviral agent
    • agents with known nephrotoxic potential:
    • aminoglycoside antibiotics (including gentamicin)
    • IV amphotericin B
    • cidofovir
    • cisplatin
    • foscarnet
    • IV pentamidine
    • IV vancomycin
    • oral or IV gancyclovir
    • other agents with significant nephrotoxic potential
    • drugs that slow renal excretion
    • probenecid
    • immune system modulators
    • systemic chemotherapeutic agents (i.e. cancer treatment medications)
    • ongoing systemic corticosteroids (with the exception of short courses of tapering steroid doses for asthma or other self- limited condition).
    • interleukin-2 (IL-2)
    • interferon (alpha, beta, or gamma)
    • other agent known to have a significant interaction with TDF or FTC
  • Proteinuria 2+ or greater by urine dipstick
  • Pregnancy (if individual has a uterus)
  • Other condition that, in the opinion of the investigator, would put the participant at risk, complicate interpretation of study outcome data, or would otherwise interfere with participation or achieving the study objectives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03086200

Layout table for location contacts
Contact: Sheldon Morris, MD MPH 619.543.8080
Contact: Eric E Ellorin, MAS 619.543.5011

Layout table for location information
United States, California
Los Angeles Lesbian, Gay, Bisexual, and Transgender Center Recruiting
Los Angeles, California, United States, 90027
Contact: Ali Talan   
Principal Investigator: Robert Bolan, MD         
University of Southern California Not yet recruiting
Los Angeles, California, United States, 90033
Contact: Connie Funk, RN    323-343-8282   
Principal Investigator: Michael Dube, MD         
Family Health Centers of San Diego Recruiting
San Diego, California, United States, 92103
Contact: Luis Salazar   
Principal Investigator: Joel Trambley, MD         
University of California, San Diego Recruiting
San Diego, California, United States, 92103
Contact: Leah Burke, MPH   
Principal Investigator: Sheldon Morris, MD MPH         
LA Biomed at Harbor-UCLA Recruiting
Torrance, California, United States, 90502
Contact: Ramiro Correa   
Principal Investigator: Katya Corado, MD         
Sponsors and Collaborators
California Collaborative Treatment Group
University of Southern California
LA Biomed at Harbor-UCLA
The Los Angeles Lesbian, Gay, Bisexual, and Transgender Center
The Family Health Centers of San Diego
Layout table for investigator information
Study Chair: Sheldon Morris, MD MPH CCTG, UCSD AVRC
Study Chair: David Moore, PhD CCTG, UCSD HNRP

Layout table for additonal information
Responsible Party: California Collaborative Treatment Group Identifier: NCT03086200     History of Changes
Other Study ID Numbers: CCTG 603
First Posted: March 22, 2017    Key Record Dates
Last Update Posted: January 15, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by California Collaborative Treatment Group:
Pre-exposure Prophylaxis
Text messaging
Motivational interviewing
Gender Non-conforming